• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Abcam plc (Amendment)

    2/12/24 5:24:03 PM ET
    $ABCM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ABCM alert in real time by email
    SC 13G/A 1 abcam_sc13ga-123123.htm AMENDMENT TO SC 13G

     

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    WASHINGTON, D.C. 20549

     


     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 3)*

     

    Abcam plc

    (Name of Issuer)

     

    Ordinary Shares 

    (Title of Class of Securities)

     

    000380204  

    (CUSIP Number)

     

    December 31, 2023 

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☒ Rule 13d-1(b) 

    ☐ Rule 13d-1(c) 

    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 000380204

     

    1

    NAMES OF REPORTING PERSONS 

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Durable Capital Partners LP 

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) 

    (a)       ☐ 

    (b)       ☐ 

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF 

    SHARES 

    BENEFICIALLY 

    OWNED BY 

    EACH 

    REPORTING 

    PERSON 

    WITH:

    5

    SOLE VOTING POWER

     

    0 

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    0 

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0 

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0% 

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA, PN

           

     

     

     

    Item 1(a).Name of Issuer:

     

    Abcam plc (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    Discovery Drive 

    Cambridge Biomedical Campus 

    Cambridge, CB2 0AX 

    United Kingdom

     

    Item 2(a).Names of Person Filing:

     

    The name of the person filing this report is: 

    Durable Capital Partners LP (the “Reporting Person”)

     

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

    The address of the principal business office of the Reporting Person is: 

    4747 Bethesda Avenue, Suite 1002 

    Bethesda, Maryland 20814

     

    Item 2(c).Citizenship or Place of Organization:

     

    The Reporting Person is a limited partnership organized under the laws of the State of Delaware.

     

    Item 2(d).Title of Class of Securities:

     

    Ordinary Shares (the “Shares”)

     

    Item 2(e).CUSIP Number:

     

    000380204

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      

    (a)☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)☒ An investment advisor in accordance with §240.13d-1(b)(1)(ii)(E).

     

    (f)☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

     

     

     

     

    (g)☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).

     

    (h)☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i)☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j)☐ A non-U.S. institution that is the functional equivalent of any of the institutions listed in § 240.13d-1 (b)(1)(ii)(A) through (I), so long as the non-U.S. institution is subject to a regulatory scheme that is substantially comparable to the regulatory scheme applicable to the equivalent U.S. institution.

     

    (k)☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    Item 4.Ownership.

     

    The information required by this item with respect to the Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G.

     

    The Reporting Person, as the investment adviser to Durable Capital Master Fund LP, has sole power to direct the vote and disposition of the Shares. Durable Capital Partners GP LLC (“Durable GP”) is the general partner of the Reporting Person, and Henry Ellenbogen is the chief investment officer of the Reporting Person and the managing member of Durable GP.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    See disclosure of relationships among parties under Item 4. The economic benefits of the Shares are shared based on agreements among the parties.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    See control and Shares holding disclosure in Item 4.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Inapplicable.

     

     

     

     

    Item 9.Notice of Dissolution of Group.

     

    Inapplicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date:February 12, 2024

     

    DURABLE CAPITAL PARTNERS LP

     

    By:/s/ Julie Jack  
     Name:  Julie Jack  
     Title:    Authorized Person  

     

     

     

    Get the next $ABCM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ABCM

    DatePrice TargetRatingAnalyst
    6/20/2023$23.00 → $22.00Outperform → Sector Perform
    RBC Capital Mkts
    6/16/2023$25.00Neutral → Buy
    BofA Securities
    12/14/2022$15.00Hold
    Deutsche Bank
    More analyst ratings

    $ABCM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Danaher Completes Acquisition of Abcam

      WASHINGTON, Dec. 6, 2023 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher") announced today it has completed its acquisition of Abcam plc (NASDAQ:ABCM) ("Abcam"). The acquisition of Abcam for $24.00 per share in cash was implemented by way of a Court-sanctioned scheme of arrangement under the UK Companies Act 2006 (the "Scheme") and the Scheme became effective in accordance with its terms on December 6, 2023. As a result, Abcam has become an indirect wholly owned subsidiary of Danaher. Trading of Abcam ADSs on Nasdaq has been suspended. The consideration due to former Abcam shareholders will be settled pursuant to the terms of the Scheme and the consideration due to former Abcam ADS

      12/6/23 7:30:00 AM ET
      $ABCM
      $DHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Machinery/Components
      Industrials
    • Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales

      Abcam plc (NASDAQ:ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE:DHR) (‘Danaher') for $24.00 per share in cash (the ‘Transaction'), to be implemented by way of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the ‘Scheme‘). The circular in relation to the Scheme was published or made available to Scheme Shareholders on October 5, 2023 (the ‘Scheme Circular‘). Abcam is pleased to announce that the Court has today issued the Court Order sanctioning the Scheme. Closing of the T

      12/4/23 4:01:00 PM ET
      $ABCM
      $DHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Machinery/Components
      Industrials
    • Abcam Acquisition by Danaher Has Received All Identified Clearances; Transaction Expected to Close on December 6, 2023

      Abcam plc (NASDAQ:ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, which entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE:DHR) (‘Danaher') for $24.00 per share in cash (the ‘Transaction'), today announced that all Identified Clearances required in connection with the Transaction have been obtained from the relevant Governmental Authorities. The Transaction remains subject to the sanction of the Scheme by the High Court of Justice of England and Wales and the satisfaction or waiver (if applicable) of certain other customary closing conditions as set out in Par

      11/17/23 7:00:00 AM ET
      $ABCM
      $DHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Machinery/Components
      Industrials

    $ABCM
    SEC Filings

    See more
    • SEC Form 15-12G filed by Abcam plc

      15-12G - Abcam plc (0001492074) (Filer)

      12/18/23 4:17:02 PM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Abcam plc

      S-8 POS - Abcam plc (0001492074) (Filer)

      12/15/23 4:24:56 PM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Abcam plc

      S-8 POS - Abcam plc (0001492074) (Filer)

      12/15/23 4:21:28 PM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ABCM
    Leadership Updates

    Live Leadership Updates

    See more
    • Jonathan Milner issues Open Letter to shareholders of Abcam plc

      Jonathan Milner issues Open Letter to shareholders of Abcam plc Highlights Company's loss of focus on governance, execution and cost control leading to value destruction and a share price materially below where it should be Outlines Milner's plan to restore shareholder trust and value and make Abcam the world leading antibody company once again CAMBRIDGE, England, 12 June 2023 – Jonathan Milner, the founder and one of the largest investors in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.3% of the Company, has today issued an open letter to the Company's shareholders calling for the removal of Peter Allen, Michael S. Baldock and Sally W. Crawford as Directors of th

      6/12/23 7:00:00 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jonathan Milner Announces That He is Taking Steps to Call an Extraordinary General Meeting of Abcam Shareholders

      Jonathan Milner Announces That He is Taking Steps to Call an Extraordinary General Meeting of Abcam Shareholders Delivers Open Letter to Abcam shareholders Follows sustained period of operational underperformance since the start of 2020 and a track record of value destruction under the current Board and leadership team Critical for shareholders to have a platform to exert their right to restore focus for Abcam on governance, execution, and cost control to elevate it to the valuation it rightly deserves CAMBRIDGE, England, 17 May 2023 – Jonathan Milner, the founder and one of the largest investors in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.3% of the Company, a

      5/17/23 9:15:00 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Abcam: Appointment of Vice President of Investor Relations

      CAMBRIDGE, England, June 27, 2022 /PRNewswire/ -- Abcam plc ("Abcam," "Company," "Group") (AIM: ABC) (NASDAQ:ABCM), a global leader in the supply of life science research tools, today announces the appointment of Tommy Thomas as Vice President of Investor Relations.     Tommy, who will be based in our Waltham, MA office, has over 20 years' experience in the life sciences sector, largely focused in the area of research tools. He joins Abcam from Avantor, where he was Vice President, Investor Relations for several years. Prior to this he was Vice President of Investor Relations, and then Chief Financial Officer of Global Services at Perkin Elmer. Before joining Perkin Elmer, Tommy spent eight

      6/27/22 2:00:00 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ABCM
    Financials

    Live finance-specific insights

    See more
    • Jonathan Milner issues Open Letter to shareholders of Abcam plc

      Jonathan Milner issues Open Letter to shareholders of Abcam plc Urges shareholders to Vote AGAINST the proposed acquisition of Abcam by Danaher Corporation CAMBRIDGE, England, 28 September 2023 – Dr. Jonathan Milner, the founder and one of the largestinvestors in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.15%, todayissued an open letter to the Company's shareholders announcing his "Vote AGAINST" campaign and providing them with the opportunity to send a clear message to the Board that they are dissatisfied with the proposed acquisition of Abcam by Danaher Corporation (NYSE:DHR) or its affiliates ("Danaher") and Abcam's governance, execution and cost control.

      9/28/23 2:00:00 AM ET
      $ABCM
      $DHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Machinery/Components
      Industrials
    • Dr. Jonathan Milner opposes Danaher's acquisition of Abcam and calls for EGM to replace Board

      Dr. Jonathan Milner opposes Danaher's acquisition of Abcam and calls for EGM to replace Board CAMBRIDGE, England, 14 September 2023 – Dr. Jonathan Milner, the founder and one of the largest investors in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.14%, today announces his decision to vote against the proposed acquisition of Abcam by Danaher Corporation (NYSE:DHR) or its affiliates ("Danaher"). In addition to this, he will formally request the Abcam Board of Directors to convene a General Meeting ("EGM") with the purpose of replacing the Company's Board, including the current CEO, CFO and Chairman. Jonathan Milner's decision to oppose the acquisition is informed by e

      9/14/23 8:00:00 AM ET
      $ABCM
      $DHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Machinery/Components
      Industrials
    • Danaher to acquire Abcam for $24.00 per Share

      Abcam plc (NASDAQ:ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, announced today that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE:DHR) (‘Danaher') will acquire all of the outstanding shares of Abcam for $24.00 per share in cash (the ‘Transaction'). The Transaction has been unanimously approved and recommended by the Abcam Board of Directors and unanimously approved by the Danaher Board of Directors. Founded in 1998 and headquartered in Cambridge, UK, Abcam offers the scientific community highly validated antibodies, reagents, biomarkers and assays to address targets in biological pat

      8/28/23 7:35:00 AM ET
      $ABCM
      $DHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Machinery/Components
      Industrials

    $ABCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Abcam plc (Amendment)

      SC 13G/A - Abcam plc (0001492074) (Subject)

      2/12/24 5:24:03 PM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Abcam plc (Amendment)

      SC 13G/A - Abcam plc (0001492074) (Subject)

      1/12/24 11:40:16 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Abcam plc (Amendment)

      SC 13D/A - Abcam plc (0001492074) (Subject)

      12/8/23 4:30:10 PM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ABCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Abcam downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded Abcam from Outperform to Sector Perform and set a new price target of $22.00 from $23.00 previously

      6/20/23 7:17:42 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Abcam upgraded by BofA Securities with a new price target

      BofA Securities upgraded Abcam from Neutral to Buy and set a new price target of $25.00

      6/16/23 7:25:35 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Deutsche Bank initiated coverage on Abcam with a new price target

      Deutsche Bank initiated coverage of Abcam with a rating of Hold and set a new price target of $15.00

      12/14/22 7:33:18 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care